Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Massachusetts General Hospital
The study objective is to determine if the administration of direct acting antivirals for 12-16 weeks after kidney transplantation prevents the spread of HCV infection from donor kidney with known HCV infection (all genotypes) to an HCV negative recipient as evidenced by a negative HCV viral RNA at 12 weeks post treatment.
Age
40–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Donor meets MGH transplant center criteria and already listed for isolated kidney transplant
No available living kidney donor
Recipient has ≤ 730 days of accrued transplant waiting time
Recipient chronic hemodialysis or peritoneal dialysis
Recipient must agree to birth control.
°.Weigh ≥ 50kg
Serum ALT within normal limits
Subject's Insurance company approves payment for DAA therapy post-kidney transplant
You may not be if
AB Blood type
HCV genotype 1
BMI \> 35
Any liver disease in recipient
Pregnant or nursing (lactating) women
Known allergy or intolerance to tacrolimus that would require administration of cyclosporine
Albumin \< 3g/dl or
Platelet count \< 75 x 103/mL
Positive crossmatch or positive donor specific antibodies
HCV RNA positive
Hepatitis B surface antigen positive
Patients with primary focal segmental glomerulosclerosis (FSGS)
Any contra-indication to kidney transplantation per our center protocol